Incyte (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Incyte" in English language version.

refsWebsite

Global rank English rank

low place

low place

572^nd place

436^th place

low place

low place

447^th place

338^th place

2,740^th place

2,050^th place

1genengnews.com

low place

6,625^th place

1swissbiotech.org

low place

low place

1businesswire.com

615^th place

407^th place

1insideindianabusiness.com

low place

low place

3,257^th place

3,398^th place

68^th place

117^th place

1businessinsider.com

140^th place

115^th place

79^th place

65^th place

1web.archive.org

1^st place

1^st place

2^nd place

2^nd place

4^th place

4^th place

1fiercepharma.com

low place

8,921^st place

ama-assn.org (Global: 3,257^th place; English: 3,398^th place)

"Baricitinib" (PDF). Statement on a nonproprietary name adopted by the USAN council. American Medical Association.

businessinsider.com (Global: 140^th place; English: 115^th place)

Ramsey, L (17 April 2017). "The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling". Business Insider.

businesswire.com (Global: 615^th place; English: 407^th place)

"Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development | Business Wire". www.businesswire.com. 29 April 2013. Retrieved 2015-12-29.

dgap.de (Global: low place; English: low place)

doi.org (Global: 2^nd place; English: 2^nd place)

Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer. 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Olumiant: Authorisation details". European Medicines Agency. 16 March 2017.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA. Archived from the original on September 28, 2019.

accessdata.fda.gov

"Drug Approval Package: Olumiant (baricitinib)". www.accessdata.fda.gov. Retrieved 2021-07-27.

fiercepharma.com (Global: low place; English: 8,921^st place)

Tracy Staton (Apr 3, 2017). "Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials". FiercePharma.

genengnews.com (Global: low place; English: 6,625^th place)

"Incyte to Co-Develop Hengrui's SHR-1210 in Up-to-$795M+ Deal". Genetic Engineering & Biotechnology News. 2 September 2015.

incyte.com (Global: low place; English: low place)

investor.incyte.com

https://investor.incyte.com/news-releases/news-release-details/incyte-appoints-bill-meury-chief-executive-officer-herve
"Incyte Acquires Maxia Pharmaceuticals; Acquisition Expands Drug Discovery & Development Programs | Incyte". February 19, 2003.{{cite web}}: CS1 maint: url-status (link)
"Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6) | Incyte". October 3, 2022.{{cite web}}: CS1 maint: url-status (link)
"Incyte Completes Acquisition of Escient Pharmaceuticals | Incyte".{{cite web}}: CS1 maint: url-status (link)

incyte.com

"Headquarters - Pharmaceutical Research & Development | Incyte". www.incyte.com. Retrieved 2021-07-27.
"portfolio.pdf" (PDF). www.incyte.com. Retrieved 2022-12-18.

insideindianabusiness.com (Global: low place; English: low place)

"Lilly, Incyte Treatment Shows Positive Results". www.insideindianabusiness.com. 9 Dec 2014. Retrieved 2 Mar 2015.{{cite web}}: CS1 maint: deprecated archival service (link)

nasdaq.com (Global: 2,740^th place; English: 2,050^th place)

"INCY". www.nasdaq.com. Retrieved 2021-07-26.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Brochez, L; Chevolet, I; Kruse, V (May 2017). "The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy". European Journal of Cancer. 76: 167–182. doi:10.1016/j.ejca.2017.01.011. PMID 28324751.

sec.gov (Global: 572^nd place; English: 436^th place)

"Incyte Corp. 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 10, 2025.
"incy_Current folio_10K". www.sec.gov. Retrieved 2021-07-26.

swissbiotech.org (Global: low place; English: low place)

"Incyte to establish European headquarters in Geneva". 15 July 2020. Retrieved 12 September 2021. New facility to serve as European base for Incyte's drug development operations, and provides efficient access to key clinical trial experts and institutions.

web.archive.org (Global: 1^st place; English: 1^st place)

Research, Center for Drug Evaluation and (2019-02-09). "Drug Trials Snapshots: OLUMIANT". FDA. Archived from the original on September 28, 2019.

wsj.com (Global: 79^th place; English: 65^th place)

Grant, Ch (14 April 2017). "Surprise FDA Rejection Will Sting This Biotech". The Wall Street Journal.